New drug tested to tame sickle cell pain crises
NCT ID NCT04662931
Summary
This study checked the safety of a drug called crizanlizumab in Indian patients with sickle cell disease. It involved 140 participants aged 16 and older who experience painful vaso-occlusive crises. The goal was to see how well patients tolerated the drug when given alongside their standard care for about one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE (SCD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Guwahati, Assam, 781003, India
-
Novartis Investigative Site
Raipur, Chhattisgarh, 492099, India
-
Novartis Investigative Site
Kozhikode, Kerala, 673008, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751003, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500082, India
-
Novartis Investigative Site
Lucknow, Uttar Pradesh, 226014, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700014, India
Conditions
Explore the condition pages connected to this study.